Table 2

PRMT5 expression in NSCLC
Cytoplasmic high PRMT5, n (%) P Nuclear high PRMT5, n (%) P Na
Age ≤60 years (n = 65) 11 (5.4) 0.36 22 (10.8) 0.55 204
>60 years (n = 139) 30 (14.7) 55 (27.0)
Gender Female (n = 53) 9 (4.1) 0.79 19 (8.8) 0.25 217
Male (n = 164) 35 (16.1) 62 (28.6)
Size ≤3 cm (n = 74) 9 (6.3) 0.09 31 (21.8) 0.35 142
>3 cm (n = 68) 18 (12.7) 22 (15.5)
Stage I (n = 81) 14 (9.9) 0.63 32 (22.7) 0.19 141
II-IV (n = 60) 13 (9.2) 21 (14.9)
Grade WD, MD (n = 55) 7 (7.2) 0.01 20 (20.6) 0.98 97
PD (n = 42) 16 (16.5) 16 (16.5)
Histology ADC (n = 113) 19 (8.3) 0.04 28 (12.2) <0.001 229
SQC (n = 116) 28 (12.2) 59 (25.8)
Survival Yes (n = 44) 9 (4.8) 0.37 14 (7.4) 0.54 189
No (n = 145) 30 (15.9) 57 (30.2)

Abbreviations: Neg negative, N number of cases, WD well differentiated, MD moderately differentiated, PD poorly differentiated, ADC adenocarcinoma, SQC squamous cell carcinoma.

aReflects total number of cases with available annotations.

Shilo et al.

Shilo et al. Diagnostic Pathology 2013 8:201   doi:10.1186/1746-1596-8-201

Open Data